Journal: Toxins

Article Title: Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults

doi: 10.3390/toxins12080511

Figure Lengend Snippet: Treatment emergent adverse events.

Article Snippet: TTX and moxifloxacin plasma concentrations were measured at BRI Biopharmaceutical Research (Vancouver, BC, Canada) and Celerion Bioanalytical Laboratory (Lincoln, NE, USA), respectively, using validated liquid chromatography with tandem mass spectroscopy (LC-MS/MS) methods with 0.025 ng mL −1 and 25.0 ng mL −1 as lower limit of quantitation for TTX and moxifloxacin, respectively.

Techniques:

Journal: Toxins

Article Title: Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults

doi: 10.3390/toxins12080511

Figure Lengend Snippet: ( A ) Change from baseline in Fridericia-corrected QTc (ΔQTcF, mean ± 90% CI) and ( B ) placebo and baseline corrected QTcF (ΔΔQTcF, mean ±90% CI) in milliseconds across treatments (15 µg TTX (●), 30 µg TTX (▲),45 µg TTX (■), 400 mg moxifloxacin (□), and placebo (∆)) for all post-dose time points.

Article Snippet: TTX and moxifloxacin plasma concentrations were measured at BRI Biopharmaceutical Research (Vancouver, BC, Canada) and Celerion Bioanalytical Laboratory (Lincoln, NE, USA), respectively, using validated liquid chromatography with tandem mass spectroscopy (LC-MS/MS) methods with 0.025 ng mL −1 and 25.0 ng mL −1 as lower limit of quantitation for TTX and moxifloxacin, respectively.

Techniques:

Journal: Toxins

Article Title: Safety, Tolerability, Pharmacokinetics, and Concentration-QTc Analysis of Tetrodotoxin: A Randomized, Dose Escalation Study in Healthy Adults

doi: 10.3390/toxins12080511

Figure Lengend Snippet: Heart rate in beats per minute across treatments (15 µg TTX (●), 30 µg TTX (▲), 45 µg TTX (■), 400 mg moxifloxacin (□), and placebo (∆)) at pre-dose and all post-dose time points.

Article Snippet: TTX and moxifloxacin plasma concentrations were measured at BRI Biopharmaceutical Research (Vancouver, BC, Canada) and Celerion Bioanalytical Laboratory (Lincoln, NE, USA), respectively, using validated liquid chromatography with tandem mass spectroscopy (LC-MS/MS) methods with 0.025 ng mL −1 and 25.0 ng mL −1 as lower limit of quantitation for TTX and moxifloxacin, respectively.

Techniques:

Journal: Case Reports in Anesthesiology

Article Title: Management of Neuraxial Analgesia in a Parturient with Factor XIII Deficiency: A Case Report and Proposed Management Algorithm

doi: 10.1155/2020/8892225

Figure Lengend Snippet: Algorithm for performing neuraxial procedures in patients with FXIII deficiency. VET: viscoelastic testing. 1 FXIII activity may be known by quantitative testing on admission, or calculated by a hematologist, taking into consideration patient's medical conditions, comorbidities, timing of last dose, and quantitative assessment of prior response during the 3 rd trimester. 2 Administration of FXIII may be necessary because of the time required to obtain results of a quantitative FXIII test. FXIII dosing should be based on the recommendation of the hematologist, targeting level above 50%. 3 FXIII also confirmed or calculated above 50% for epidural catheter removal.

Article Snippet: Prior to this pregnancy, she had been on infusions of 45 U/kg of Factor XIII Concentrate (Corifact, CSL Behring) every four weeks.

Techniques: Activity Assay